Back to the future of oridonin: Again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo

Cell Research

Volumn 17, Issue 4, 2007, Pages 274-276

  Zhou, Guang Biao ^a,b   Chen, Sai Juan ^a   Wang, Zhen Yi ^a   Chen, Zhu ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DITERPENE; HERBACEOUS AGENT; KAURANE DERIVATIVE; ONCOPROTEIN; ORIDONIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NOTE; RABDOSIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DITERPENES; DITERPENES, KAURANE; DRUGS, CHINESE HERBAL; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; ONCOGENE PROTEINS, FUSION; RABDOSIA; TUMOR CELLS, CULTURED;

EID: 34247360358     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2007.21     Document Type: Note

References (18)

1. Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Berlin: Springer-Verlag. 1992:817-847.
2. Qinghaosu antimalaria coordinating research group. Antimalaria studies on Qinghaosu. Chin Med J (Engl) 1979; 92:811-816.
3. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005; 81:71-78.
4. Li SZ. The compendium of materia medica (Originally published in the Ming Dynasty of China, 1578). Beijing: People's Medical Publishing House. 1982.
5. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345-3353.
6. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with Arsenic Trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315-3324.
7. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
8. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992; 12:170-171.
9. Fujita E, Fujita T, Katayama H, Shibuya M. Terpenoids. Part XV. Structure and absolute configuration of oridonin isolated from Isodon japonicus trichocarpus. J Chem Soc (Chem Comm) 1970; 21:1674-1681.
10. Henan Medical Institute, Henan Medical College, Yunnan Institute of Botany. Oridonin-a new antitumor subject. Chin Science Bull 1978; 23:53-56.
11. Fujita T, Takeda Y, Sun HD, et al. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta Med 1988; 54:414-417.
12. Fujita E, Nagao Y, Node M, et al. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia 1976; 32:203-206.
13. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572.
14. Zhou GB, Chen SJ, Chen Z. Acute promyelocytic leukemia: a model of molecular target based therapy. Hematology 2005; 10 Suppl 1:270-280.
15. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88:1052-1061.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-2333.
17. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102:1104-1109.
18. Zhou GB, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2006 Dec 29; doi: 10.1182/blood-2006-06-032250